Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Filociclovir - Microbiotix

Next Previous
Drug Profile

Filociclovir - Microbiotix

Alternative Names: CPV; Cyclopropavir; MBX-400; NSC-D745998; ZSM-I-62

Latest Information Update: 28 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wayne State University School of Medicine
  • Developer Microbiotix
  • Class Antivirals; Cyclopropanes; Hypoxanthines; Purinones; Small molecules
  • Mechanism of Action DNA-directed DNA polymerase inhibitors; Ganciclovir kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Adenovirus infections
  • No development reported Cytomegalovirus infections

Most Recent Events

  • 28 Jul 2023 No recent reports of development identified for phase-I development in Cytomegalovirus infections(In volunteers) in USA (PO, Capsule)
  • 25 Aug 2020 Filociclovir is still in phase I trials for Cytomegalovirus infections in the US (Microbiotix pipeline August 2020)
  • 25 Aug 2020 Preclinical trials in Adenovirus infections in USA (unspecified route) (Microbiotix pipeline August 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top